|
1
|
Griffioen AW and Molema G: Angiogenesis:
Potentials for pharmacologic intervention in the treatment of
cancer, cardiovascular diseases, and chronic inflammation.
Pharmacol Rev. 52:237–268. 2000.PubMed/NCBI
|
|
2
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mayo KH, Haseman J, Ilyina E and Gray B:
Designed beta-sheet-forming peptide 33mers with potent human
bactericidal/permeability increasing protein-like bactericidal and
endotoxin neutralizing activities. Biochim Biophys Acta.
1425:81–92. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Griffioen AW, van der Schaft DW,
Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF and Mayo
KH: Anginex, a designed peptide that inhibits angiogenesis. Biochem
J. 354:233–242. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ilyina E, Roongta V and Mayo KH: NMR
structure of a de novo designed, peptide 33mer with two distinct,
compact beta-sheet folds. Biochemistry. 36:5245–5250. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dings RP, Arroyo MM, Lockwood NA, van Eijk
LI, Haseman JR, Griffioen AW and Mayo KH: Beta-sheet is the
bioactive conformation of the anti-angiogenic anginex peptide.
Biochem J. 373:281–288. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Schaft DW, Dings RP, de Lussanet
QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC,
Wagstaff J, Mayo KH and Griffioen AW: The designer anti-angiogenic
peptide anginex targets tumor endothelial cells and inhibits tumor
growth in animal models. FASEB J. 16:1991–1993. 2002.PubMed/NCBI
|
|
8
|
Mayo KH, van der Schaft DW and Griffioen
AW: Designed beta-sheet peptides that inhibit proliferation and
induce apoptosis in endothelial cells. Angiogenesis. 4:45–51. 2001.
View Article : Google Scholar
|
|
9
|
Dings RP, van der Schaft DW, Hargittai B,
Haseman J, Griffioen AW and Mayo KH: Anti-tumor activity of the
novel angiogenesis inhibitor anginex. Cancer Lett. 194:55–66. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brandwijk RJ, Nesmelova I, Dings RP, Mayo
KH, Thijssen VL and Griffioen AW: Cloning an artificial gene
encoding angiostatic anginex: From designed peptide to functional
recombinant protein. Biochem Biophys Res Commun. 333:1261–1268.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong DF, Li EX, Wang JB, Wu YY, Shi F, Guo
JJ, Wu Y, Liu JP, Liu SX and Yang GX: Anti-angiogenesis and
anti-tumor effects of AdNT4-anginex. Cancer Lett. 285:218–224.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li EX, Liu SX, Yang GX, Wang QY, Wu YY and
Shi F: Construction and identification of the recombinant
prokaryotic expression plasmid containingbetapep-25 peptide. Xi Bao
Yu Fen Zi Mian Yi Xue Za Zhi. 22:154–160. 2006.In Chinese.
|
|
13
|
Berns KI and Giraud C: Adenovirus and
adeno-associated virus as vectors for gene therapy. Ann NY Acad
Sci. 772:95–104. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Samulski RJ, Zhu X, Xiao X, Brook JD,
Housman DE, Epstein N and Hunter LA: Targeted integration of
adeno-associated virus (AAV) into human chromosome 19. EMBO J.
10:3941–3950. 1991.PubMed/NCBI
|
|
15
|
Kotin RM, Menninger JC, Ward DC and Berns
KI: Mapping and direct visualization of a region-specific viral DNA
integration site on chromosome 19q13-qter. Genomics. 10:831–834.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kotin RM, Linden RM and Berns KI:
Characterization of a preferred site on human chromosome 19q for
integration of adeno-associated virus DNA by non-homologous
recombination. EMBO J. 11:5071–5078. 1992.PubMed/NCBI
|
|
17
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gupta SK and Singh JP: Inhibition of
endothelial cell proliferation by platelet factor-4 involves a
unique action on S phase progression. J Cell Biol. 127:1121–1127.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang JB, Wang MD, Li EX and Dong DF:
Advances and prospects of anginex as a promising anti-angiogenesis
and anti-tumor agent. Peptides. 38:457–462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Muise-Helmericks RC, Grimes HL, Bellacosa
A, Malstrom SE, Tsichlis PN and Rosen N: Cyclin D expression is
controlled post-transcriptionally via a phosphatidylinositol
3-kinase/Akt-dependent pathway. J Biol Chem. 273:29864–29872. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xin M and Deng X: Nicotine inactivation of
the proapoptotic function of Bax through phosphorylation. J Biol
Chem. 280:10781–10789. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Henshall DC, Araki T, Schindler CK, Lan
JQ, Tiekoter KL, Taki W and Simon RP: Activation of
Bcl-2-associated death protein and counter-response of Akt within
cell populations during seizure-induced neuronal death. J Neurosci.
22:8458–8465. 2002.PubMed/NCBI
|
|
23
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pianetti S, Arsura M, Romieu-Mourez R,
Coffey RJ and Sonenshein GE: Her-2/neu overexpression induces
NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated
degradation of IkappaB-alpha that can be inhibited by the tumor
suppressor PTEN. Oncogene. 20:1287–1299. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tabruyn SP, Mémet S, Avé P, Verhaeghe C,
Mayo KH, Struman I, Martial JA and Griffioen AW: NF-kappaB
activation in endothelial cells is critical for the activity of
angiostatic agents. Mol Cancer Ther. 8:2645–2654. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen F, Castranova V and Shi X: New
insights into the role of nuclear factor-kappaB in cell growth
regulation. Am J Pathol. 159:387–397. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu J and Lin A: Wiring the cell signaling
circuitry by the NF-kappa B and JNK1 crosstalk and its applications
in human diseases. Oncogene. 26:3267–3278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thijssen VL, Postel R, Brandwijk RJ, Dings
RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG,
Bakkers J, et al: Galectin-1 is essential in tumor angiogenesis and
is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA.
103:15975–15980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brandwijk RJ, Dings RP, van der Linden E,
Mayo KH, Thijssen VL and Griffioen AW: Anti-angiogenesis and
anti-tumor activity of recombinant anginex. Biochem Biophys Res
Commun. 349:1073–1078. 2006. View Article : Google Scholar : PubMed/NCBI
|
